| |
original article |
Date |
Title |
Authors All Authors |
| 1 |
[GO] |
2024―Apr―12 |
SARS-CoV-2 mitochondrial metabolic and epigenomic reprogramming in COVID-19 |
Joseph W. Guarnieri, Jeffrey A. Haltom, Yentli E. Soto Albrecht, Timothy Lie, Arnold Z. Olali, Gabrielle A. Widjaja, et al. (+4) Sujata S. Ranshing, Alessia Angelin, Deborah Murdock, Douglas C. Wallace |
| 2 |
[GO] |
2023―Sep―09 |
Risk of drug-drug interactions in China's fight against COVID-19 and beyond |
Qingpeng Zhang, Jiannan Yang, Daniel Dajun Zeng, Yibin Feng, Ian C.K. Wong |
| 3 |
[GO] |
2023―Jul―20 |
An innovative strategy to investigate microbial protein modifications in a reliable fast and sensitive way: a therapy oriented proof of concept based on UV-C irradiation of SARS-CoV-2 spike protein |
Sergio Strizzi, Letizia Bernardo, Pasqualina D’Ursi, Chiara Urbinati, Andrea Bianco, Fiona Limanaqi, et al. (+10) Andrea Manconi, Maria Milanesi, Alberto Macchi, Dario Di Silvestre, Adalberto Cavalleri, Giovanni Pareschi, Marco Rusnati, Mario Clerici, PierLuigi Mauri, Mara Biasin |
| 4 |
[GO] |
2023―Feb―15 |
Beneficial Effects of L-Arginine in Patients Hospitalized for COVID-19: New Insights from a Randomized Clinical Trial |
Valentina Trimarco, Raffaele Izzo, Angela Lombardi, Antonietta Coppola, Giuseppe Fiorentino, Gaetano Santulli |
| 5 |
[GO] |
2022―Dec―10 |
The elusive role of proton pump inhibitors in COVID-19: can plasma Chromogranin A levels hold the key? |
Clara Sciorati, Rebecca De Lorenzo, Nicola I. Lorè, Cristina Tresoldi, Daniela M. Cirillo, Fabio Ciceri, et al. (+3) Angelo Corti, Angelo A. Manfredi, Patrizia Rovere-Querini |
| 6 |
[GO] |
2022―Nov―04 |
Efficacy of mucosal vaccination using a protozoan parasite as a vehicle for antigen delivery: IgG and neutralizing response after rectal administration of LeCoVax-2, a candidate vaccine against COVID-19 |
Sara Epis, Ilaria Varotto-Boccazzi, Alessandro Manenti, Diego Rubolini, Paolo Gabrieli, Giulia Maria Cattaneo, et al. (+13) Louise Gourlay, Francesca Dapporto, Martina Monti, Ilaria Razzano, Margherita Leonardi, Iannacone Matteo, Camilla Recordati, Luca Bertola, Paolo Fiorina, Luigi Marvasi, Emanuele Montomoli, Gianvincenzo Zuccotti, Claudio Bandi |
| 7 |
[GO] |
2022―Oct―13 |
Glucocorticoids and COVID-19 |
Stefano Bruscoli, Pier Giorgio Puzzovio, Maria Zaimi, Katerina Tiligada, Francesca Levi-Schaffer, Carlo Riccardi |
| 8 |
[GO] |
2022―Oct―01 |
Long COVID symptoms survey and methodological issue |
Cheng-Hsien Hung, James Cheng-Chung Wei |
| 9 |
[GO] |
2022―Sep―30 |
Beneficial Effects of Vitamin C and L-Arginine in the Treatment of Post-Acute Sequelae of COVID-19 |
Gaetano Santulli, Valentina Trimarco, Bruno Trimarco, Raffaele Izzo |
| 10 |
[GO] |
2022―Sep―16 |
Pharmacological targeting of HMGB-1 translocation: A potential therapeutic strategy for COVID-19 |
Vahid Bagheri |
| 11 |
[GO] |
2022―Sep―14 |
Confounding Factors for Developing Long COVID |
Chi-Kuei Hsu, Chih-Cheng Lai |
| 12 |
[GO] |
2022―Sep―13 |
Concerns About Methodology on “Curbing COVID-19 progression and mortality with traditional Chinese medicine among hospitalized patients with COVID-19” |
Renin Chang, Cheuk-Kwan Sun, Yao-Min Hung |
| 13 |
[GO] |
2022―Sep―09 |
Comment on ‘Curbing COVID-19 progression and mortality with traditional Chinese medicine among hospitalized patients with COVID-19: A propensity score-matched analysis’ by Tseng et al. |
Pei-Yun Shih, Su-Boon Yong, James Cheng-Chung Wei |
| 14 |
[GO] |
2022―Sep―09 |
Treating COVID-19 with NRICM101 and NRICM102 - author’s reply 3 |
Yu-Hwei Tseng, Sunny Jui-Shan Lin, Ming-Yung Lee, Yi-Chang Su |
| 15 |
[GO] |
2022―Sep―09 |
Treating COVID-19 with NRICM101 and NRICM102 - author’s reply |
Sunny Jui-Shan Lin, Ming-Yung Lee, Yu-Hwei Tseng, Yi-Chang Su |
| 16 |
[GO] |
2022―Sep―09 |
Treating COVID-19 with NRICM101 and NRICM102 - author’s reply 2 |
Ming-Yung Lee, Yu-Hwei Tseng, Sunny Jui-Shan Lin, Yi-Chang Su |
| 17 |
[GO] |
2022―Sep―08 |
The true effect of traditional Chinese medicine on the clinical outcome of hospitalized patients with COVID-19? |
Chi-Kuei Hsu, Chih-Cheng Lai, Jui-Hsiang Wang |
| 18 |
[GO] |
2022―Sep―05 |
Targeting spike protein-induced TLR/NET axis by COVID-19 therapeutic NRICM102 ameliorates pulmonary embolism and fibrosis |
Wen-Chi Wei, Chia-Ching Liaw, Keng-Chang Tsai, Chun-Tang Chiou, Yu-Hwei Tseng, Wen-Fei Chiou, et al. (+8) Yu-Chi Lin, Chia-I Tsai, Chen-Shien Lin, Chen-Sung Lin, Kuo-Tong Liou, I-Shing Yu, Yuh-Chiang Shen, Yi-Chang Su |
| 19 |
[GO] |
2022―Aug―23 |
Curbing COVID-19 progression and mortality with traditional Chinese medicine among hospitalized patients with COVID-19: A propensity score-matched analysis |
Yu-Hwei Tseng, Sunny Jui-Shan Lin, Sheng-Mou Hou, Chih-Hung Wang, Shun-Ping Cheng, Kung-Yen Tseng, et al. (+23) Ming-Yung Lee, Shen-Ming Lee, Yi-Chia Huang, Chien-Jung Lin, Chi-Kuei Lin, Tsung-Lung Tsai, Chen-Shien Lin, Ming-Huei Cheng, Tieng-Siong Fong, Chia-I Tsai, Yu-Wen Lu, Jung-Chih Lin, Yi-Wen Huang, Wei-Chen Hsu, Hsien-Hwa Kuo, Li-Hsiang Wang, Chia-Ching Liaw, Wen-Chi Wei, Keng-Chang Tsai, Yuh-Chiang Shen, Wen-Fei Chiou, Jaung-Geng Lin, Yi-Chang Su |
| 20 |
[GO] |
2022―Jun―30 |
Tissue repair strategies: What we have learned from COVID-19 in the application of MSCs therapy |
Yiran E. Li, Amir Ajoolabady, Muralikrishnan Dhanasekaran, Jun Ren |
| 21 |
[GO] |
2022―Jun―09 |
Clinical impact and disease evolution of SARS-CoV-2 infection in familial Mediterranean fever |
Francesca Marinelli, Chiara Caporilli, Annachiara Titolo, Donato Rigante, Susanna Esposito |
| 22 |
[GO] |
2022―May―20 |
Estimating the effectiveness of remdesivir on risk of COVID-19 mortality: The role of observational data |
Andrea Giacomelli, Alessandro Cozzi-Lepri, Giacomo Casalini, Letizia Oreni, Anna Lisa Ridolfo, Spinello Antinori |
| 23 |
[GO] |
2022―Apr―01 |
COVID-19 and The Promise of Small Molecule Therapeutics: Are There Lessons to be Learnt? |
Wei Shen Ho, Ruirui Zhang, Yeong Lan Tan, Christina Li Lin Chai |
| 24 |
[GO] |
2022―Mar―11 |
Timely Treatment and Higher Compliance to Traditional Chinese Medicine: New Influencing Factors for Reducing Severe COVID-19 based on Retrospective Cohorts in 2020 and 2021 |
Ying Zhang, Yangyang Liu, Ming Li, Shaohua Feng, Xiuyang Li, Zezheng Gao, et al. (+2) Yingying Yang, Xiaolin Tong |
| 25 |
[GO] |
2021―Dec―31 |
Systemic administration of glucocorticoids, cardiovascular complications and mortality in patients hospitalised with COVID-19, SARS, MERS or influenza: a systematic review and meta-analysis of randomised trials |
Elisabetta Caiazzo, Asma O.M. Rezig, Dario Bruzzese, Armando Ialenti, Carla Cicala, John G.F. Cleland, et al. (+3) Tomasz J. Guzik, Pasquale Maffia, Pierpaolo Pellicori |
| 26 |
[GO] |
2021―Dec―23 |
Corrigendum to “DNA aptamers masking angiotensin converting enzyme 2 as an innovative way to treat SARS-CoV-2 pandemic” |
Alessandro Villa, Electra Brunialti, Jessica Dellavedova, Clara Meda, Monica Rebecchi, Matteo Conti, et al. (+5) Lorena Donnici, Raffaele De Francesco, Angelo Reggiani, Vincenzo Lionetti, Paolo Ciana |
| 27 |
[GO] |
2021―Nov―19 |
Corrigendum to: Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2) [Pharmacol. Res. 156 (2020) 104761] |
Li Runfeng, Hou Yunlong, Huang Jicheng, Pan Weiqi, Ma Qinhai, Shi Yongxia, et al. (+12) Li Chufang, Zhao Jin, Jia Zhenhua, Jiang Haiming, Zheng Kui, Huang Shuxiang, Dai Jun, Li Xiaobo, Hou Xiaotao, Wang Lin, Zhong Nanshan, Yang Zifeng |
| 28 |
[GO] |
2021―Nov―16 |
DNA aptamers masking angiotensin converting enzyme 2 as an innovative way to treat SARS-CoV-2 pandemic. |
Alessandro Villa, Electra Brunialti, Jessica Dellavedova, Clara Meda, Monica Rebecchi, Matteo Conti, et al. (+5) Lorena Donnici, Raffaele De Francesco, Angelo Reggiani, Vincenzo Lionetti, Paolo Ciana |
| 29 |
[GO] |
2021―Oct―29 |
Guidelines on the treatment with integrated traditional Chinese medicine and western medicine for severe coronavirus disease 2019 |
Zhi-Yu Li, Zhi-Jun Xie, Hai-Chang Li, Jian-Jian Wang, Xiang-Hui Wen, Shou-Yuan Wu, et al. (+27) Jiao Chen, Juan-Juan Zhang, Lin Li, Qiang-Qiang Guo, Qiu-Ping Liu, Hui Lan, Yue-Peng Jiang, Dian-Ming Li, Xiao-Feng Xu, Si-Yue Song, Ming Zhang, Shan Fang, Wei-Dong Lai, Yi-Ni Gao, Feng-Qi Zhang, Wen-Qing Luo, Yu Lou, Wu Chen, Xia-Feng Zhang, Ke-Er Wang, Ming-Qian Zhou, Yuan-Fang He, An-Ran Xi, Yan Gao, Yi Zhang, Yao-Long Chen, Cheng-Ping Wen |
| 30 |
[GO] |
2021―Aug―26 |
Sex-tailored pharmacology and COVID-19: next steps towards appropriateness and health equity |
Andrea Spini, Valentina Giudice, Vincenzo Brancaleone, Maria Grazia Morgese, Silvia De Francia, Amelia Filippelli, et al. (+5) Anna Ruggieri, Marina Ziche, Elena Ortona, Andrea Cignarella, Luigia Trabace |
| 31 |
[GO] |
2021―Aug―14 |
Identification of Natural Compounds as SARS-CoV-2 Entry Inhibitors by Molecular Docking-based Virtual Screening with Bio-layer Interferometry |
Dingqi Zhang, Sami Hamdoun, Ruihong Chen, Lijun Yang, Chi Kio Ip, Yuanqing Qu, et al. (+6) Runfeng Li, Haiming Jiang, Zifeng Yang, Sookja Kim Chung, Liang Liu, Vincent Kam Wai Wong |
| 32 |
[GO] |
2021―Jun―03 |
Remdesivir in moderate to severe COVID-19: a matter of time? |
Cecilia Bonazzetti, Andrea Giacomelli, Martina Pavia, Chiara Fusetti, Martina Gerbi, Francesco Petri, et al. (+4) Andrea Poloni, Letizia Oreni, Anna Lisa Ridolfo, Spinello Antinori |
| 33 |
[GO] |
2021―May―09 |
A bibliometric study of COVID-19 research in Web of Science |
Meiming Su, Suowen Xu, Jianping Weng |
| 34 |
[GO] |
2021―Apr―07 |
Corrigendum to “Naringerin as candidate drug against SARS-CoV-2: The role for TPC2 genomic variants in COVID-19” [Pharmacol. Res. 164 (2021) 105402] |
Emilio Di Maria, Paolo Martini, Massimo Gennarelli |
| 35 |
[GO] |
2021―Apr―02 |
A new stratification model for a population health risk assessment, based on a large cohort of patients infected by Covid-19 |
Roberto Blaco, Olivia Leoni, Gjiliola Cukaj, Michele Ercolanoni, Carla Carnovale |
| 36 |
[GO] |
2021―Mar―27 |
Understanding the Heart-Brain Axis Response in COVID-19 patients: a Suggestive Perspective for Therapeutic Development |
Vincenzo Lionetti, Sveva Bollini, Raffaele Coppini, Andrea Gerbino, Alessandra Ghigo, Guido Iaccarino, et al. (+16) Rosalinda Madonna, Fabio Mangiacapra, Michele Miragoli, Francesco Moccia, Luca Munaron, Pasquale Pagliaro, Astrid Parenti, Teresa Pasqua, Claudia Penna, Federico Quaini, Carmine Rocca, Michele Samaja, Laura Sartiani, Teresa Soda, Carlo Gabriele Tocchetti, Tommaso Angelone |
| 37 |
[GO] |
2021―Mar―06 |
Associations between COVID-19 and 30-day thromboembolic events and mortality in people with dementia receiving antipsychotic medications |
Stephanie L. Harrison, Benjamin J.R. Buckley, Deirdre A. Lane, Paula Underhill, Gregory Y.H. Lip |
| 38 |
[GO] |
2021―Feb―16 |
International policies and challenges on the legalization of traditional medicine/herbal medicines in the fight against COVID-19 |
Yin Xiong, Min Gao, Bert van Duijn, Hoyoung Choi, Frits van Horssen, Mei Wang |
| 39 |
[GO] |
2021―Jan―30 |
Anticoagulant or antiplatelet use and severe COVID-19 disease: A propensity score-matched territory-wide study |
Jiandong Zhou, Sharen Lee, Cosmos Liutao Guo, Carlin Chang, Tong Liu, Keith Sai Kit Leung, et al. (+4) Abraham Ka Chung Wai, Bernard Man Yung Cheung, Gary Tse, Qingpeng Zhang |
| 40 |
[GO] |
2020―Dec―25 |
CONSUMPTION OF ANTIBIOTICS AT AN ITALIAN UNIVERSITY HOSPITAL DURING THE EARLY MONTHS OF THE COVID-19 PANDEMIC: WERE ALL ANTIBIOTIC PRESCRIPTIONS APPROPRIATE? |
Andrea Giacomelli, Anna Lisa Ridolfo, Letizia Oreni, Stefania Vimercati, Maria Albrecht, Dario Cattaneo, et al. (+4) Sara Giordana Rimoldi, Giuliano Rizzardini, Massimo Galli, Spinello Antinori |
| 41 |
[GO] |
2020―Dec―24 |
Naringerin as candidate drug against SARS-CoV-2: The role for TPC2 genomic variants in COVID-19 |
Emilio Di Maria, Paolo Martini, Massimo Gennarelli |
| 42 |
[GO] |
2020―Dec―17 |
Saliva sampling for chasing SARS-CoV-2: A Game-changing strategy |
Elisa Borghi, Valentina Massa, Daniela Carmagnola, Claudia Dellavia, Chiara Parodi, Emerenziana Ottaviano, et al. (+5) Arianna Sangiorgio, Lucia Barcellini, Greta Gambacorta, Federica Forlanini, Gian Vincenzo Zuccotti |
| 43 |
[GO] |
2020―Dec―16 |
Methodological education in response to the quality of COVID-19 publications |
Felicita Andreotti, Cristina Gervasoni, Giuseppe Di Pasquale, Aldo P. Maggioni |
| 44 |
[GO] |
2020―Nov―13 |
Letter to the Editor in response to the articles ‘Lianhuaqingwen exerts anti-viral and anti-inflammatory activities against novel coronavirus (SARS-CoV-2)’ and ‘Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-κB signaling pathway.’ |
Xi Huang, Qiulong Zhao, Liang Xia, Shaoqi Shi |
| 45 |
[GO] |
2020―Nov―09 |
Association between early treatment with Qingfei Paidu decoction and favorable clinical outcomes in patients with COVID-19: a retrospective multicenter cohort study |
Nannan Shi, Bin Liu, Ning Liang, Yan Ma, Youwen Ge, Honggang Yi, et al. (+86) Hongmei Wo, Heng Gu, Yuan Kuang, Shaowen Tang, Yang Zhao, Lin Tong, Sihong Liu, Chen Zhao, Renbo Chen, Weiguo Bai, Yipin Fan, Zhan Shi, Li Li, Jia Liu, Hao Gu, Yingjie Zhi, Zhifei Wang, Yuanyuan Li, Huizhen Li, Jingya Wang, Liwen Jiao, Yaxin Tian, Yibai Xiong, Ruili Huo, Xiaohui Zhang, Jiangfeng Bai, Hong Chen, Liying Chen, Qiao Feng, Tuanmao Guo, Yong Hou, Guifen Hu, Xiaomei Hu, Yunhong Hu, Jin Huang, Qiuhua Huang, Shaozhen Huang, Liang Ji, Haihao Jin, Xiao Lei, Chunyan Li, Guihui Wu, Jike Li, Minqing Li, Quntang Li, Xianyong Li, Hongde Liu, Jinping Liu, Zhang Liu, Yuting Ma, Ya Mao, Liufen Mo, Hui Na, Jingwei Wang, Fangli Song, Sheng Sun, Dongting Wang, Mingxuan Wang, Xiaoyan Wang, Yinzhen Wang, Yudong Wang, Wei Wu, Lanping Wu, Yanhua Xiao, Haijun Xie, Hongming Xu, Shoufang Xu, Ruixia Xue, Chun Yang, Kaijun Yang, Puye Yang, Shengli Yuan, Gongqi Zhang, Jinbo Zhang, Linsong Zhang, Shusen Zhao, Wanying Zhao, Kai Zheng, Yingchun Zhou, Junteng Zhu, Tianqing Zhu, Guangxi Li, Wei Wang, Huamin Zhang, Yanping Wang, Yongyan Wang |
| 46 |
[GO] |
2020―Nov―05 |
Letter to the Editor in response to the article ‘Candidate drugs against SARS-CoV-2 and COVID-19’ |
Ilaria Campesi, Andrea Montella, Flavia Franconi F |
| 47 |
[GO] |
2020―Oct―20 |
NARINGENIN IS A POWERFUL INHIBITOR OF SARS-CoV-2 INFECTION IN VITRO |
Nicola Clementi, Carolina Scagnolari, Antonella D’Amore, Fioretta Palombi, Elena Criscuolo, Federica Frasca, et al. (+6) Alessandra Pierangeli, Nicasio Mancini, Guido Antonelli, Massimo Clementi, Armando Carpaneto, Antonio Filippini |
| 48 |
[GO] |
2020―Oct―13 |
Meta-analysis on outcome-worsening comorbidities of COVID-19 and related potential drug-drug interactions |
Awortwe Charles, Cascorbi Ingolf |
| 49 |
[GO] |
2020―Aug―29 |
Chinese herbal medicine supplementation therapy on COVID-19 |
Mingyang Yu, Rongguang Zhang, Peng Ni, Guangcai Duan |
| 50 |
[GO] |
2020―Aug―15 |
Covid-19 Pandemic: a frontline hospital reorganization to cope with therapeutic and diagnostic emergency |
Giuseppe De Filippis, Laura Cavazzana, Alessandra Gimigliano, Mariagrazia Piacenza, Stefania Vimercati |
| 51 |
[GO] |
2020―Aug―10 |
Hanshiyi Formula, an approved medicine for Sars-CoV2 infection in China, reduced the proportion of mild and moderate COVID-19 patients turning to severe status: A cohort study |
Jiaxing Tian, Shiyan Yan, Han Wang, Ying Zhang, Yujiao Zheng, Haoran Wu, et al. (+9) Xiuyang Li, Zezheng Gao, Yanke Ai, Xiaowen Gou, Lei Zhang, Liyun He, Fengmei Lian, Baoyan Liu, Xiaolin Tong |
| 52 |
[GO] |
2020―Aug―08 |
Efficacy of Huoxiang Zhengqi dropping pills and Lianhua Qingwen granules in treatment of COVID-19: A randomized controlled trial |
Mingzhong Xiao, Jiaxing Tian, Yana Zhou, Xi Xu, Xiaojun Min, Yi Lv, et al. (+22) Miao Peng, Ying Zhang, Dengying Yan, Suping Lang, Qing Zhang, An Fan, Jia Ke, Xiuyang Li, Binbin Liu, Manhong Jiang, Quan Liu, Jinyue Zhu, Lu Yang, Zheng Zhu, Kun Zeng, Chengyin Li, Yujiao Zheng, Haoran Wu, Jiaran Lin, Fengmei Lian, Xiaodong Li, Xiaolin Tong |
| 53 |
[GO] |
2020―Aug―04 |
COVID-19: pharmacology and kinetics of viral clearance |
Nicola Farina, Giuseppe A. Ramirez, Rebecca De Lorenzo, Luigi Di Filippo, Caterina Conte, Fabio Ciceri, et al. (+2) Angelo A. Manfredi, Patrizia Rovere-Querini |
| 54 |
[GO] |
2020―Jul―31 |
Acute kidney injury is associated with severe infection and fatality in patients with COVID-19: a systematic review and meta-analysis of 40 studies and 25,278 patients |
Mengjiao Shao, XiaoMei Li, Fen Liu, Ting Tian, Junyi Luo, Yining Yang |
| 55 |
[GO] |
2020―Jul―12 |
Data to guide the application of the new WHO criteria for releasing COVID-19 patients from isolation |
Andrea Foppiani, Simona Bertoli, Alberto Battezzati, Gianvincenzo Zuccotti |
| 56 |
[GO] |
2020―Jul―09 |
Analysis on the Current Quality Standards of Chinese Materia Medica Used in COVID-19 Prevention and Treatment |
Yan-Hong Shi, Yu-Feng Huang, Wang Wang-Ying, Li Yang, Hua Zhou, Zhen Sang |
| 57 |
[GO] |
2020―Jul―09 |
The study on the treatment of Xuebijing injection (XBJ) in adults with severe or critical Corona Virus Disease 2019 and the inhibitory effect of XBJ against SARS-CoV-2 |
Qinhai Ma, Minshan Qiu, Hongxia Zhou, Jie Chen, Xue Yang, Zhenxuan Deng, et al. (+8) Liping Chen, Jinchao Zhou, Yuping Liao, Qimin Chen, Qianwei Zheng, Lihua Cai, Lihan Shen, Zifeng Yang |
| 58 |
[GO] |
2020―Jul―03 |
Clinical course of COVID-19 in 41 patients with immune-mediated inflammatory diseases: experience from Humanitas Center, Milan |
Mariangela Allocca, Giacomo Maria Guidelli, Riccardo G. Borroni, Carlo Selmi, Alessandra Narcisi, Silvio Danese, Gionata Fiorino |
| 59 |
[GO] |
2020―Jul―02 |
Chinese herbal medicine for coronavirus disease 2019: a systematic review and meta-analysis |
Xingjiang Xiong, Pengqian Wang, Kelei Su, William C. Cho, Yanwei Xing |
| 60 |
[GO] |
2020―Jun―30 |
Mortality in COVID-19 patients treated with ACEIs/ARBs: re-estimated meta-analysis results following the Mehra et al. retraction |
Ahmad Alamer, Ivo Abraham |
| 61 |
[GO] |
2020―Jun―30 |
Edaravone: a potential treatment for the COVID-19-induced inflammatory syndrome? |
Sandra E. Reznik, Amit K. Tiwari, Charles R. Ashby |
| 62 |
[GO] |
2020―Jun―27 |
Targeting inflammation and cytokine storm in COVID-19 |
Qianwen Huang, Xiumei Wu, Xueying Zheng, Sihui Luo, Suowen Xu, Jianping Weng |
| 63 |
[GO] |
2020―Jun―23 |
The database-based strategy may overstate the potential effects of traditional Chinese medicine against COVID-19 |
Yu-Xi Huang, Wen-Xiao Wang, Sai Zhang, Yu-Ping Tang, Shi-Jun Yue |
| 64 |
[GO] |
2020―Jun―20 |
Network pharmacological approach for elucidating the mechanisms of traditional Chinese medicine in treating COVID-19 patients |
Hu-Dan Pan, Xiao-Jun Yao, Wan-Ying Wang, Hung-Yan Lau, Liang Liu |
| 65 |
[GO] |
2020―Jun―18 |
Effect of combination antiviral therapy on hematological profiles in 151 adults hospitalized with severe coronavirus disease 2019 |
Xin Li, Yi Yang, Lancong Liu, Xuefeng Yang, Xiaobo Zhao, Yan Li, et al. (+8) Yanyan Ge, Yuxin Shi, Ping Lv, Jianchu Zhang, Tao Bai, Hua Zhou, Pei Luo, Shilong Huang |
| 66 |
[GO] |
2020―Jun―17 |
Statins and other drugs: Facing COVID-19 as a vascular disease |
Fabian Sanchis-Gomar, Carme Perez-Quilis, Emmanuel J. Favaloro, Giuseppe Lippi |
| 67 |
[GO] |
2020―Jun―09 |
East meets West in COVID-19 therapeutics |
Shanshan Wang, Xian Zeng, Yali Wang, Yufen Zhao, Weiping Chen, Yu Zong Chen |
| 68 |
[GO] |
2020―Jun―04 |
Would ACEIs/ARBs be beneficial for COVID-19 patients without hypertension? |
Ying Huang, Changming Xie, Xiaoke Chen, Qianhui Hong, Hui Huang |
| 69 |
[GO] |
2020―Jun―02 |
Databases for facilitating mechanistic investigations of traditional Chinese medicines against COVID-19 |
Sida Jiang, Qiuji Cui, Bingwei Ni, Yingying Chen, Ying Tan, Weiping Chen, Yu Zong Chen |
| 70 |
[GO] |
2020―May―29 |
Clinical impact of pre-admission antithrombotic therapy in hospitalized patients with COVID-19: a multicenter observational study |
Vincenzo Russo, Marco Di Maio, Emilio Attena, Angelo Silverio, Fernando Scudiero, Dario Celentani, et al. (+2) Corrado Lodigiani, Pierpaolo Di Micco |
| 71 |
[GO] |
2020―May―28 |
Angiotensin receptor blockers for the treatment of covid-19 and its comorbidities |
Juan M. Saavedra |
| 72 |
[GO] |
2020―May―28 |
Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system |
Shuofeng Yuan, Jasper F.W. Chan, Kenn K.H. Chik, Chris C.Y. Chan, Jessica O.L. Tsang, Ronghui Liang, et al. (+10) Jianli Cao, Kaiming Tang, Lin-Lei Chen, Kun Wen, Jian-Piao Cai, Zi-Wei Ye, Gang Lu, Hin Chu, Dong-Yan Jin, Kwok-Yung Yuen |
| 73 |
[GO] |
2020―May―25 |
COVID-19 and Kawasaki Disease in Children |
Suowen Xu, Mingwu Chen, Jianping Weng |
| 74 |
[GO] |
2020―May―23 |
Enhanced platelet inhibition treatment improves hypoxemia in patients with severe Covid-19 and hypercoagulability. A case control, proof of concept study |
Maurizio Viecca, Dejan Radovanovic, Giovanni Battista Forleo, Pierachille Santus |
| 75 |
[GO] |
2020―May―23 |
Biochemical indicators of coronavirus disease 2019 exacerbation and the clinical implications |
Peng-jiao An, Zhun Zhu Yi, Li-ping Yang |
| 76 |
[GO] |
2020―May―22 |
30-day mortality in patients hospitalized with COVID-19 during the first wave of the Italian epidemic: a prospective cohort study |
Andrea Giacomelli, Anna Lisa Ridolfo, Laura Milazzo, Letizia Oreni, Dario Bernacchia, Matteo Siano, et al. (+19) Cecilia Bonazzetti, Alice Covizzi, Marco Schiuma, Matteo Passerini, Marco Piscaglia, Massimo Coen, Guido Gubertini, Giuliano Rizzardini, Chiara Cogliati, Anna Maria Brambilla, Riccardo Colombo, Antonio Castelli, Roberto Rech, Agostino Riva, Alessandro Torre, Luca Meroni, Stefano Rusconi, Spinello Antinor, Massimo Galli |
| 77 |
[GO] |
2020―May―21 |
Review on the potential action mechanisms of Chinese medicines in treating Coronavirus Disease 2019 (COVID-19) |
Yu-Feng Huang, Chen Bai, Fan He, Ying Xie, Hua Zhou |
| 78 |
[GO] |
2020―May―20 |
A review of therapeutic agents and Chinese herbal medicines against SARS-COV-2 (COVID-19) |
Fangfang Huang, Ying Li, Elaine Lai-Han Leung, Xiaohua Liu, Kaifeng Liu, Qu Wang, et al. (+6) Yongqi Lan, Xiaoling Li, Haibing Yu, Liao Cu, Hui Luo, Lianxiang Luo |
| 79 |
[GO] |
2020―May―20 |
Letter to the Editor in response to the article “Could IL-17 represent a new therapeutic target for the treatment and/or management of COVID-19-related respiratory syndrome?” |
Gabriele Ceccarelli, Katiuscia Nardi, Francesca Marchesani |
| 80 |
[GO] |
2020―May―15 |
ACEI/ARB Use and Risk of Infection or Severity or Mortality of COVID-19: A Systematic Review and Meta-analysis |
Xue Zhang, Jiong Yu, Li-ya Pan, Hai-yin Jiang |
| 81 |
[GO] |
2020―May―13 |
The possible mechanisms of action of 4-aminoquinolines (chloroquine/hydroxychloroquine) against Sars-Cov-2 infection (COVID-19): A role for iron homeostasis? |
Eugenia Quiros Roldan, Giorgio Biasiotto, Paola Magro, Isabella Zanella |
| 82 |
[GO] |
2020―May―13 |
COVID-19, hypertension and cardiovascular diseases: Should we change the therapy? |
Marijana Tadic, Cesare Cuspidi, Giuseppe Mancia, Raffaella Dell’Oro, Guido Grassi |
| 83 |
[GO] |
2020―May―13 |
Rho kinase inhibitors for SARS-CoV-2 induced acute respiratory distress syndrome: Support from Bartter’s and Gitelman’s syndrome patients |
Lorenzo A. Calò, Giovanni Bertoldi, Paul A. Davis |
| 84 |
[GO] |
2020―May―11 |
Efficacy and Safety of Integrated Traditional Chinese and Western Medicine for Corona Virus Disease 2019 (COVID-19): a systematic review and meta-analysis |
Ming Liu, Ya Gao, Yuan Yuan, Kelu Yang, Shuzhen Shi, Junhua Zhang, Jinhui Tian |
| 85 |
[GO] |
2020―May―11 |
Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post_treatment hospitalisation status |
Spinello Antinori, Maria Vittoria Cossu, Anna Lisa Ridolfo, Roberto Rech, Cecilia Bonazzetti, Gabriele Pagani, et al. (+21) Guido Gubertini, Massimo Coen, Carlo Magni, Antonio Castelli, Beatrice Borghi, Riccardo Colombo, Riccardo Giorgi, Elena Angeli, Davide Mileto, Laura Milazzo, Stefania Vimercati, Martina Pellicciotta, Mario Corbellino, Alessandro Torre, Stefano Rusconi, Letizia Oreni, Maria Rita Gismondo, Andrea Giacomelli, Luca Meroni, Giuliano Rizzardini, Massimo Galli |
| 86 |
[GO] |
2020―May―11 |
Does lopinavir really inhibit SARS-CoV-2? |
Dario Cattaneo, Mario Corbellino, Emilio Clementi, Massimo Galli, Agostino Riva, Cristina Gervasoni |
| 87 |
[GO] |
2020―May―07 |
Brief recommendations on the management of adult patients with familial hypercholesterolemia during the COVID-19 pandemic |
Maciej Banach, Peter E. Penson, Zlatko Fras, Michal Vrablik, Daniel Pella, Željko Reiner, et al. (+4) Seyed Mohammad Nabavi, Amirhossein Sahebkar, Meral Kayikcioglu, Magdalena Daccord |
| 88 |
[GO] |
2020―May―06 |
The CoV-2 outbreak: how hematologists could help to fight Covid-19 |
Sara Galimberti, Chiara Baldini, Claudia Baratè, Federica Ricci, Serena Balducci, Susanna Grassi, et al. (+8) Francesco Ferro, Gabriele Buda, Edoardo Benedetti, Rita Fazzi, Laura Baglietto, Ersilia Lucenteforte, Antonello Di Paolo, Mario Petrini |
| 89 |
[GO] |
2020―May―05 |
The clinical benefits of Chinese patent medicines against COVID-19 based on current evidence |
Dan Zhang, Bing Zhang, Jin-Tao Lv, Ri-Na Sa, Xiao-Meng Zhang, Zhi-Jian Lin |
| 90 |
[GO] |
2020―May―03 |
The pros and cons of traditional Chinese medicines in the treatment of COVID-19 |
Yali Wang, Xian Zeng, Yufen Zhao, Weiping Chen, Yu Zong Chen |
| 91 |
[GO] |
2020―Apr―30 |
Efficacy and safety of current therapeutic options for COVID-19 - lessons to be learnt from SARS and MERS epidemic: A systematic review and meta-analysis |
Han Zhong, Yan Wang, Zai-Li Zhang, Yang-Xi Liu, Ke-Jia Le, Min Cui, et al. (+4) Yue-Tian Yu, Zhi-Chun Gu, Yuan Gao, Hou-Wen Lin |
| 92 |
[GO] |
2020―Apr―30 |
Chemical composition and pharmacological mechanism of Qingfei Paidu Decoction and Ma Xing Shi Gan Decoction against Coronavirus Disease 2019 (COVID-19): in silico and experimental study |
Ruocong Yang, Hao Liu, Chen Bai, Yingchao Wang, Xiaohui Zhang, Rui Guo, et al. (+7) Siying Wu, Jianxun Wang, Elaine Leung, Hang Chang, Peng Li, Tiegang Liu, Yi Wang |
| 93 |
[GO] |
2020―Apr―30 |
Nitazoxanide/Azithromycin combination for COVID-19: A suggested new protocol for COVID-19 early management |
Mina T. Kelleni |
| 94 |
[GO] |
2020―Apr―30 |
Epidemiological and Clinical Characteristics Analysis of COVID-19 in the Surrounding Areas of Wuhan, Hubei Province in 2020 |
Yi Zheng, Chang Xiong, Yuquan Liu, Xin Qian, Yijun Tang, Liang Liu, et al. (+2) Elaine Lai-Han Leung, Meifang Wang |
| 95 |
[GO] |
2020―Apr―30 |
Current targeted therapeutics against COVID-19: based on first-line experience in china |
Yue Zhang, Qianhao Xu, Zhuoyan Sun, Lei Zhou |
| 96 |
[GO] |
2020―Apr―30 |
Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-κB signaling pathway |
Qinhai Ma, Weiqi Pan, Runfeng Li, Bin Liu, Chufang Li, Yuqi Xie, et al. (+9) Zhoulang Wang, Jin Zhao, Haiming Jiang, Jicheng Huang, Yongxia Shi, Jun Dai, Kui Zheng, Xiaobo Li, Zifeng Yang |
| 97 |
[GO] |
2020―Apr―30 |
Possible use of the mucolytic drug, bromhexine hydrochloride, as a prophylactic agent against SARS-CoV-2 infection based on its action on the Transmembrane Serine Protease 2 |
Solomon Habtemariam, Seyed Fazel Nabavi, Saeid Ghavami, Cosmin Andrei Cismaru, Ioana Berindan Neagoe, Seyed Mohammad Nabavi |
| 98 |
[GO] |
2020―Apr―29 |
Candidate drugs against SARS-CoV-2 and COVID-19 |
Dwight L. McKee, Ariane Sternberg, Ulrike Stange, Stefan Laufer, Cord Naujokat |
| 99 |
[GO] |
2020―Apr―29 |
NSAIDs in patients with viral infections, including Covid-19: victims or perpetrators? |
Annalisa Capuano, Cristina Scavone, Giorgio Racagni, Francesco Scaglione |
| 100 |
[GO] |
2020―Apr―22 |
Repurposing the mucolytic cough suppressant and TMPRSS2 protease inhibitor bromhexine for the prevention and management of SARS-CoV-2 infection |
Roberto Maggio, Giovanni U. Corsini |
| 101 |
[GO] |
2020―Apr―21 |
Darunavir does not prevent SARS-CoV-2 infection in HIV patients |
Agostino Riva, Federico Conti, Dario Bernacchia, Laura Pezzati, Salvatore Sollima, Stefania Merli, et al. (+5) Matteo Siano, Angelica Lupo, Stefano Rusconi, Dario Cattaneo, Cristina Gervasoni |
| 102 |
[GO] |
2020―Apr―15 |
Angiotensin Receptor Blockers and 2019-nCoV |
Juan M. Saavedra |
| 103 |
[GO] |
2020―Apr―14 |
Could IL-17 represent a new therapeutic target for the treatment and/or management of COVID-19-related respiratory syndrome? |
Gian Marco Casillo, Adel Abo Mansour, Federica Raucci, Anella Saviano, Nicola Mascolo, Asif Jilani Iqbal, Francesco Maione |
| 104 |
[GO] |
2020―Apr―14 |
Physiological and pathological regulation of ACE2, the SARS-CoV-2 receptor |
Yanwei Li, Wei Zhou, Li Yang, Ran You |
| 105 |
[GO] |
2020―Apr―11 |
Plausibility of therapeutic effects of Rho kinase inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (COVID-19) |
Farshad Abedi, Ramin Rezaee, Gholamreza Karimi |
| 106 |
[GO] |
2020―Apr―11 |
Statins in coronavirus outbreak: it’s time for experimental and clinical studies |
Maurizio Bifulco, Patrizia Gazzerro |
| 107 |
[GO] |
2020―Apr―03 |
The use of Traditional Chinese Medicines to treat SARS-CoV-2 may cause more harm than good |
Paul E. Gray, Yvonne Belessis |
| 108 |
[GO] |
2020―Apr―03 |
Reply to “The use of traditional Chinese medicines to treat SARS-CoV-2 may cause more harm than good” |
Ai-Hua Zhang, Jun-Ling Ren, Xi-Jun Wang |
| 109 |
[GO] |
2020―Apr―02 |
3CLpro inhibitors as a potential therapeutic option for COVID-19: Available evidence and ongoing clinical trials |
Mekonnen Sisay |
| 110 |
[GO] |
2020―Mar―25 |
Corrigendum to “Traditional Chinese medicine for COVID-19 treatment” [Pharmacol. Res. 155 (2020) 104743] |
Jun-ling Ren, Ai-Hua Zhang, Xi-Jun Wang |
| 111 |
[GO] |
2020―Mar―20 |
Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2) |
Li Runfeng, Hou Yunlong, Huang Jicheng, Pan Weiqi, Ma Qinhai, Shi Yongxia, et al. (+12) Li Chufang, Zhao Jin, Jia Zhenhua, Jiang Haiming, Zheng Kui, Huang Shuxiang, Dai Jun, Li Xiaobo, Hou Xiaotao, Wang Lin, Zhong Nanshan, Yang Zifeng |
| 112 |
[GO] |
2020―Mar―04 |
Traditional Chinese Medicine for COVID-19 Treatment |
Jun-ling Ren, Ai-Hua Zhang, Xi-Jun Wang |
|
